Reuters logo
Israel's Mitoconix Bio raises $20 million in private funding round
June 27, 2017 / 10:47 AM / in 6 months

Israel's Mitoconix Bio raises $20 million in private funding round

JERUSALEM (Reuters) - Mitoconix Bio, an Israeli biopharmaceutical company focused on treating neurological diseases, said on Tuesday it raised $20 million in an early funding round.

The round was led by Remiges Ventures with participation from OrbiMed, Dementia Discovery Fund, Arix Bioscience, RMGP Bio-Pharma investment Fund and others.

The proceeds will be used to advance Mitoconix Bio’s product for the treatment of Huntington’s disease through pre-clinical and clinical development and to expand its pipeline to treat additional neurodegenerative disorders by improving mitochondrial function.

Reporting by Steven Scheer

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below